JPWO2020010308A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020010308A5 JPWO2020010308A5 JP2021500040A JP2021500040A JPWO2020010308A5 JP WO2020010308 A5 JPWO2020010308 A5 JP WO2020010308A5 JP 2021500040 A JP2021500040 A JP 2021500040A JP 2021500040 A JP2021500040 A JP 2021500040A JP WO2020010308 A5 JPWO2020010308 A5 JP WO2020010308A5
- Authority
- JP
- Japan
- Prior art keywords
- fzd
- binding region
- wnt
- lrp5
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023186681A JP2024001292A (ja) | 2018-07-05 | 2023-10-31 | 多特異性Ｗｎｔ代替分子及びその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862694339P | 2018-07-05 | 2018-07-05 | |
| US62/694,339 | 2018-07-05 | ||
| US201862782122P | 2018-12-19 | 2018-12-19 | |
| US62/782,122 | 2018-12-19 | ||
| US201962797772P | 2019-01-28 | 2019-01-28 | |
| US62/797,772 | 2019-01-28 | ||
| PCT/US2019/040687 WO2020010308A1 (en) | 2018-07-05 | 2019-07-05 | Multi-specific wnt surrogate molecules and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023186681A Division JP2024001292A (ja) | 2018-07-05 | 2023-10-31 | 多特異性Ｗｎｔ代替分子及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021529796A JP2021529796A (ja) | 2021-11-04 |
| JPWO2020010308A5 true JPWO2020010308A5 (https=) | 2022-07-12 |
| JP2021529796A5 JP2021529796A5 (https=) | 2022-07-12 |
Family
ID=69059929
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500040A Pending JP2021529796A (ja) | 2018-07-05 | 2019-07-05 | 多特異性Ｗｎｔ代替分子及びその使用 |
| JP2023186681A Pending JP2024001292A (ja) | 2018-07-05 | 2023-10-31 | 多特異性Ｗｎｔ代替分子及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023186681A Pending JP2024001292A (ja) | 2018-07-05 | 2023-10-31 | 多特異性Ｗｎｔ代替分子及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210292422A1 (https=) |
| EP (2) | EP4733325A2 (https=) |
| JP (2) | JP2021529796A (https=) |
| CN (2) | CN120623353A (https=) |
| AU (1) | AU2019297522B2 (https=) |
| CA (1) | CA3104526A1 (https=) |
| DK (1) | DK3820906T3 (https=) |
| ES (1) | ES3058239T3 (https=) |
| PL (1) | PL3820906T3 (https=) |
| WO (1) | WO2020010308A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7305543B2 (ja) | 2017-01-26 | 2023-07-10 | スロゼン オペレーティング， インコーポレイテッド | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
| CN111699003B (zh) * | 2017-12-19 | 2024-05-03 | 瑟罗泽恩奥普瑞汀公司 | 抗lrp5/6抗体和使用方法 |
| CN111655729B (zh) * | 2017-12-19 | 2023-10-20 | 瑟罗泽恩奥普瑞汀公司 | 抗卷曲蛋白抗体和使用方法 |
| EP3732201A4 (en) | 2017-12-19 | 2022-04-20 | Surrozen Operating, Inc. | WNT SURROGATES AND THEIR USES |
| US20210032352A1 (en) * | 2018-02-14 | 2021-02-04 | Antera Therapeutics Inc. | Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof |
| JP2021530223A (ja) | 2018-07-09 | 2021-11-11 | スロゼン， インコーポレイテッド | 組織特異性Ｗｎｔシグナル増強分子及びその使用 |
| AU2020300618A1 (en) * | 2019-07-02 | 2022-01-27 | Surrozen Operating, Inc. | Monospecific anti-frizzled antibodies and methods of use |
| CN115427446A (zh) * | 2020-02-24 | 2022-12-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt超级激动剂 |
| TW202233656A (zh) | 2020-11-16 | 2022-09-01 | 美商蘇羅森營運公司 | 肝特異性wnt訊號增強分子及其用途 |
| WO2022130342A1 (en) * | 2020-12-18 | 2022-06-23 | Antlera Therapeutics Inc. | Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof |
| WO2023250402A2 (en) * | 2022-06-22 | 2023-12-28 | Antlera Therapeutics Inc. | Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof |
| WO2023130055A2 (en) * | 2021-12-31 | 2023-07-06 | Surrozen Operating, Inc. | Wnt receptor-specific compound and method relating thereto |
| AU2024279826A1 (en) * | 2023-05-29 | 2026-01-08 | Surrozen Operating, Inc. | Wnt surrogate agents and methods for lacrimal gland regeneration |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US20030044409A1 (en) | 2001-05-01 | 2003-03-06 | Carson Dennis A. | Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| CA2548817A1 (en) | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| PL1776384T3 (pl) | 2004-08-04 | 2013-10-31 | Mentrik Biotech Llc | WARIANTY REGIONÓW Fc |
| DE102004050620A1 (de) | 2004-10-13 | 2006-04-20 | Eberhard-Karls-Universität Tübingen | Monoklonaler Antikörper gegen Frizzled-Rezeptoren |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| EP1810035A4 (en) | 2004-11-10 | 2010-03-17 | Macrogenics Inc | GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION |
| AU2005325801A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| CA2602663A1 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc variants with optimized properties |
| DE102005035568A1 (de) | 2005-07-25 | 2007-02-01 | M-Phasys Gmbh | Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| CN101573383B (zh) | 2006-06-21 | 2015-05-13 | 肿瘤疗法科学股份有限公司 | 靶向肿瘤的针对卷曲同源物10的单克隆抗体及其用途 |
| KR20100091170A (ko) * | 2007-11-02 | 2010-08-18 | 노파르티스 아게 | 저밀도-지단백질 수용체-관련 단백질 ６ (ｌｒｐ６)을 조정하기 위한 분자 및 방법 |
| CA2705923A1 (en) | 2007-11-16 | 2009-05-22 | Nuvelo, Inc. | Antibodies to lrp6 |
| CN103002911B (zh) | 2008-09-26 | 2015-08-26 | 昂考梅德药品有限公司 | 卷曲蛋白结合药剂及其应用 |
| ES2579909T3 (es) | 2009-02-03 | 2016-08-17 | Koninklijke Nederlandse Akademie Van Wetenschappen | Medio de cultivo para células madre epiteliales y organoides que comprenden dichas células madre |
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| AR080795A1 (es) | 2010-03-24 | 2012-05-09 | Genentech Inc | Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6) |
| CA2794674A1 (en) | 2010-04-01 | 2011-10-06 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| EP3033356B1 (en) | 2013-08-14 | 2020-01-15 | Sachdev Sidhu | Antibodies against frizzled proteins and methods of use thereof |
| GB2519786A (en) * | 2013-10-30 | 2015-05-06 | Sergej Michailovic Kiprijanov | Multivalent antigen-binding protein molecules |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
| US11142577B2 (en) * | 2014-09-12 | 2021-10-12 | The Board Of Trustees Of The Leland Stanford Junior University | WNT signaling agonist molecules |
| WO2016205566A1 (en) | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function |
| US10766962B2 (en) | 2015-06-16 | 2020-09-08 | The Regents Of The University Of California | FZD7 specific antibodies and vaccines to treat cancer and control stem cell function |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| KR102802241B1 (ko) * | 2015-12-04 | 2025-05-07 | 베링거 인겔하임 인터내셔날 게엠베하 | 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드 |
| US10919968B2 (en) | 2016-01-29 | 2021-02-16 | Modmab Therapeutics Corporation | Frizzled5 protein-binding agents |
| RU2767329C2 (ru) | 2016-02-06 | 2022-03-17 | Эпимаб Биотерапьютикс, Инк. | Иммуноглобулин с тандемными fab-фрагментами и варианты его применения |
| EP3732201A4 (en) * | 2017-12-19 | 2022-04-20 | Surrozen Operating, Inc. | WNT SURROGATES AND THEIR USES |
| US20210032352A1 (en) * | 2018-02-14 | 2021-02-04 | Antera Therapeutics Inc. | Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof |
-
2019
- 2019-07-05 CA CA3104526A patent/CA3104526A1/en active Pending
- 2019-07-05 EP EP25208409.0A patent/EP4733325A2/en active Pending
- 2019-07-05 CN CN202510662154.5A patent/CN120623353A/zh active Pending
- 2019-07-05 ES ES19830971T patent/ES3058239T3/es active Active
- 2019-07-05 AU AU2019297522A patent/AU2019297522B2/en active Active
- 2019-07-05 WO PCT/US2019/040687 patent/WO2020010308A1/en not_active Ceased
- 2019-07-05 DK DK19830971.8T patent/DK3820906T3/da active
- 2019-07-05 CN CN201980052601.8A patent/CN112566940B/zh active Active
- 2019-07-05 US US17/257,817 patent/US20210292422A1/en active Pending
- 2019-07-05 EP EP19830971.8A patent/EP3820906B1/en active Active
- 2019-07-05 JP JP2021500040A patent/JP2021529796A/ja active Pending
- 2019-07-05 PL PL19830971.8T patent/PL3820906T3/pl unknown
-
2023
- 2023-10-31 JP JP2023186681A patent/JP2024001292A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529796A5 (https=) | ||
| JP2021508247A5 (https=) | ||
| JP2021508683A5 (https=) | ||
| JPWO2020010308A5 (https=) | ||
| JP6634158B2 (ja) | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体及びその使用 | |
| CN112566940B (zh) | 多特异性wnt替代分子和其用途 | |
| JP6647208B2 (ja) | 抗ｉｌ−１７抗体、その生産および使用のための方法 | |
| JP5918275B2 (ja) | 変形性関節症及び疼痛の治療 | |
| JP6321545B2 (ja) | 治療法における使用のための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP6224608B2 (ja) | 血液循環を安定化させるための、患者の急性疾患又は急性病態の治療法における使用に向けた、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP6321544B2 (ja) | 慢性若しくは急性疾患又は急性病態に罹患している患者の死亡リスクを低減するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| CN111655729B (zh) | 抗卷曲蛋白抗体和使用方法 | |
| CN118271444A (zh) | Wnt替代分子和其用途 | |
| US9840554B2 (en) | Antibodies against platelet-derived growth factor (PDGF) | |
| JP6193872B2 (ja) | 慢性又は急性疾患に罹患している患者の体液平衡を調整するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP2026016376A5 (https=) | ||
| JP2013523184A5 (https=) | ||
| CN116917332A (zh) | 四价fzd和wnt共受体结合抗体分子及其用途 | |
| JP2023504699A (ja) | 治療および診断のための新規な分子 | |
| JP2021508683A (ja) | 抗ｌｒｐ５／６抗体及び使用方法 | |
| CN106687478A (zh) | 新的抗人Tie‑2抗体 | |
| JPWO2019126399A5 (https=) | ||
| JPWO2019126401A5 (https=) | ||
| JP5225109B2 (ja) | ヒトｈｍｇｂ−１に特異的に結合する抗体を有効成分として含有する治療剤 | |
| US20250304675A1 (en) | Compositions and methods for treating ischemic heart disease |